GlassScriptPhysician profile
Stuart W H Pang
NPI 1093855603
$2,202.50
in general payments reported to CMS, 2019-2025
12 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $743 · 2021: $199 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $581.55 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $280.55 | 2019 | |
| Medtronic USA, INC. | $236.96 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $195.32 | 2020-2025 | |
| Lilly USA, LLC | $165.96 | 2019 | |
| Boston Scientific Corporation | $145.53 | 2020 | |
| Portola Pharmaceuticals, LLC | $125.00 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $124.80 | 2020 | |
| Greenwich Biosciences, INC. | $118.74 | 2019 | |
| Livanova USA, INC. | $112.15 | 2019 | |
| Allergan, INC. | $67.02 | 2020 | |
| Abbott Laboratories | $48.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.